A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase IIb Efficacy and Safety Study of Adjunctive AZD6765 in Patients With Major Depressive Disorder (MDD) and a History of Inadequate Response to Antidepressants

Trial Profile

A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase IIb Efficacy and Safety Study of Adjunctive AZD6765 in Patients With Major Depressive Disorder (MDD) and a History of Inadequate Response to Antidepressants

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Apr 2017

At a glance

  • Drugs Lanicemine (Primary)
  • Indications Major depressive disorder
  • Focus Therapeutic Use
  • Sponsors AstraZeneca
  • Most Recent Events

    • 01 Aug 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 12 Jun 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 11 Jun 2012 Additional trial locations (Chile, Slovakia, South Africa) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top